SCYNEXIS (SCYX) Stock Price, News & Analysis

Company Overview

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Key Stats

• Today's Range: $1.19 to $1.27
• 50-Day Range: $1.20 to $1.63
• 52-Week Range: $1.19 to $3.07
• Volume: 223,927 shs
• Average Volume: 183,571 shs
• Market Capitalization: $45.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

SCYNEXIS Stock Analysis - MarketRank™

SCYNEXIS scored higher than 49% of companies evaluated by MarketBeat, and ranked 653rd out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for SCYNEXIS.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SCYNEXIS are expected to grow in the coming year, from ($0.55) to $0.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of SCYNEXIS is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of SCYNEXIS is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

SCYNEXIS has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.28% of the outstanding shares of SCYNEXIS have been sold short.

Short Interest Ratio / Days to Cover

SCYNEXIS has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in SCYNEXIS has recently decreased by 10.17%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SCYNEXIS does not currently pay a dividend.

Dividend Growth

SCYNEXIS does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.28% of the outstanding shares of SCYNEXIS have been sold short.

Short Interest Ratio / Days to Cover

SCYNEXIS has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in SCYNEXIS has recently decreased by 10.17%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.06

News Sentiment

SCYNEXIS has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for SCYNEXIS this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added SCYNEXIS to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, SCYNEXIS insiders have bought more of their company's stock than they have sold. Specifically, they have bought $27,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 2.85% of the stock of SCYNEXIS is held by insiders.

Percentage Held by Institutions

54.37% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SCYX Stock Analysis - Frequently Asked Questions

How have SCYX shares performed this year?

SCYNEXIS's stock was trading at $2.23 at the start of the year. Since then, SCYX shares have decreased by 46.2% and is now trading at $1.20.
View the best growth stocks for 2024 here.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) announced its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.14. The firm had revenue of $0.66 million for the quarter. SCYNEXIS had a negative trailing twelve-month return on equity of 66.21% and a negative net margin of 425.41%.

When did SCYNEXIS's stock split?

SCYNEXIS shares reverse split on Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 16th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are SCYNEXIS's major shareholders?

Top institutional shareholders of SCYNEXIS include D.A. Davidson & CO. (1.39%), Geode Capital Management LLC (1.05%), Wealth Effects LLC (0.27%) and XTX Topco Ltd (0.05%). Insiders that own company stock include Gonzalez David Angulo, Marco Taglietti and Scott Sukenick.
View institutional ownership trends.

How do I buy shares of SCYNEXIS?

Shares of SCYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some other companies that SCYNEXIS investors own include Zomedica (ZOM), Jumia Technologies (JMIA), NIO (NIO), Nano Dimension (NNDM), Sorrento Therapeutics (SRNE), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 11/17/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SCYX
• CUSIP: N/A
• CIK: 1178253
• Web: www.scynexis.com
• Phone: (201) 884-5485
• Fax: 201-884-5490
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.74)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $67.04 million
• Net Margins: -425.41%
• Pretax Margin: -422.22%
• Return on Equity: -66.21%
• Return on Assets: -38.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.13
• Quick Ratio: 3.13

Sales & Book Value

• Annual Sales: $140.14 million
• Price / Sales: 0.32
• Cash Flow: $1.90 per share
• Price / Cash Flow: 0.63
• Book Value: $1.54 per share
• Price / Book: 0.78

Miscellaneous

• Outstanding Shares: 37,950,000
• Free Float: 36,867,000
• Market Cap: $45.54 million
• Optionable: Optionable
• Beta: 1.50